The key finding
A 2026 systematic review and meta-analysis of 11 studies involving 1,406 adults with schizophrenia found that caffeine consumption does not significantly affect overall symptom severity when measured by standard psychiatric rating scales. However, individual studies within the analysis showed contradictory patterns: some reported improvements in negative symptoms such as apathy and social withdrawal, while others documented increased positive symptoms including hallucinations and delusions. The research highlights that caffeine’s impact on schizophrenia appears multifaceted rather than uniformly beneficial or harmful.
What the study looked like
Researchers conducted a PRISMA-guided systematic review, searching six academic databases for all English-language studies published through December 30, 2024. They screened 252 articles and ultimately included 11 studies with a combined total of 1,406 adult participants diagnosed with schizophrenia. The included studies compared people with different levels of caffeine intake and measured outcomes across three domains: cognitive function, psychiatric symptoms, and daily functioning. The research team used a random-effects meta-analysis model to combine results, calculating Hedges’ g for effect sizes and I² statistics to measure how much variability existed between studies. The review was prospectively registered with PROSPERO, an international database for systematic review protocols, ensuring methodological transparency.
Why researchers think this happened
The authors suggest that caffeine’s complex pharmacological profile may explain these mixed results. Caffeine acts as an adenosine receptor antagonist, affecting dopamine transmission in the brain—the same neurotransmitter system disrupted in schizophrenia and targeted by antipsychotic medications. This dual action could theoretically improve the motivational deficits characteristic of negative symptoms while simultaneously overstimulating pathways involved in positive symptoms like psychosis. The researchers noted significant heterogeneity in study designs, caffeine dosages, and patient populations, which likely contributed to inconsistent findings. They also raised the possibility that caffeine might interact unpredictably with antipsychotic medications, either enhancing or interfering with their therapeutic effects, though the current evidence base doesn’t allow for definitive conclusions about these interactions.
How to read this carefully
This meta-analysis faces several important limitations that prevent drawing firm conclusions. The 11 included studies varied substantially in design, caffeine measurement methods, and outcome assessments, creating high heterogeneity that makes direct comparisons difficult. Most studies were observational rather than randomized controlled trials, meaning they can identify associations but cannot prove causation—people who consume more caffeine might differ systematically from those who consume less in ways that affect symptoms independently. The research doesn’t establish optimal caffeine doses, timing, or which specific patient subgroups might benefit versus experience harm. Additionally, the potential for caffeine to interact with various antipsychotic medications remains poorly understood, and individual metabolic differences in caffeine processing weren’t accounted for across studies.
What this means for everyday life
For people living with schizophrenia and their care providers, this research suggests that caffeine consumption should be approached individually rather than through blanket recommendations. Given the mixed findings, it might be worth having conversations with mental health professionals about personal caffeine habits, especially if you notice changes in motivation, social engagement, or symptom intensity that seem related to coffee, tea, or energy drink consumption. The study doesn’t support eliminating caffeine entirely or using it as a therapeutic strategy, but rather highlights the importance of monitoring how it affects your specific symptom pattern. Since caffeine may interact with antipsychotic medications, any significant changes to caffeine intake should ideally be discussed with prescribing clinicians who can watch for unexpected medication effects or symptom fluctuations.